Navigation Links
GW professor discovers new information in the understanding of autism and genetics
Date:1/3/2013

WASHINGTON (Jan. 3, 2012) Research out of the George Washington University (GW), published in the journal Proceedings of the National Academy of Sciences (PNAS), reveals another piece of the puzzle in a genetic developmental disorder that causes behavioral diseases such as autism. Anthony-Samuel LaMantia, Ph.D., professor of pharmacology and physiology at the GW School of Medicine and Health Sciences (SMHS) and director of the GW Institute for Neuroscience, along with post-doctoral fellow Daniel Meechan, Ph.D. and Thomas Maynard, Ph.D., associate research professor of pharmacology and physiology at GW SMHS, authored the study titled "Cxcr4 regulation of interneuron migration is disrupted in 22q11.2 deletion syndrome."

For the past nine years, LaMantia and his colleagues have been investigating how behavioral disorders such as autism, attention deficit hyperactivity disorder (ADHD), and schizophrenia arise during early brain development. His work published in PNAS focuses specifically on the effects diminished 22q11.2 gene dosage has on cortical circuit development.

This research shows for the first time that genetic lesions known to be associated with autism and other behavioral diseases disrupt cellular and molecular mechanisms that ensure normal development of a key type of cortical neuron: the interneuron. LaMantia and his colleagues had found previously that one type of cortical neuron, the projection neuron, is not generated in appropriate numbers during development in a mouse model of 22q11 Deletion Syndrome. In the current study published in PNAS, LaMantia found that interneurons, while made in the right numbers at their birthplace outside of the cortex, are not able to move properly into the cortex where they are needed to control cortical circuit activity. The research shows that the main reason they don't move properly is due to diminished expression of activity of a key regulatory pathway for migration, the Cxcr4 cytokine receptor.

"This gives us two pieces of the puzzle for this genetic developmental disorder," said LaMantia. "These two pieces tell us that in very early development, those with 22q11.2 deletion syndrome do not make enough cells in one case, and do not put the other cells in the right place. This occurs not because of some degenerative change, but because the mechanisms that make these cells and put them in the right place during the first step of development have gone awry due to mutation."

The next step in LaMantia's research is to probe further into the molecular mechanisms that disrupt the proliferation of projection neurons and migration of interneurons. "If we understand that better and understand its consequences, we can go about fixing it," said LaMantia. "We want to understand why cortical circuits don't get built properly due to the genetic deletion of chromosome 22."


'/>"/>

Contact: Lisa Anderson
lisama2@gwu.edu
202-994-3121
George Washington University
Source:Eurekalert

Related biology news :

1. National Academy of Inventors names four UT Arlington professors as charter fellows
2. Association of Environmental Engineering and Science Professors name Environmental Engineering Science as its official journal
3. University of Tennessee engineering professor looks to whirligig beetle for bio-inspired robots
4. Increasing drought stress challenges vulnerable hydraulic system of plants, GW professor finds
5. GW professor to examine infections in HIV patients with federal grant
6. Michael Barnett of Boston College named Professor of the Year for Massachusetts
7. NJIT professor promotes building material of millennium: Autoclave aerated concrete
8. The IPCC Report on Climate Change - Swedish professor Thomas Sterner selected as 1 of the experts
9. Louisiana Tech University professor earns national honor from Society of American Foresters
10. New book on physics principles by Wayne State professor explains life as we know it
11. SMU professor Louis Jacobs honored with prestigious award from Texas science teachers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, a ... emerging technology, announces the availability of a new report, Sensors ... Continue Reading ... ... and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... 27, 2017 Four US Biotech ... today, and they are: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), ... Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals Inc. (NASDAQ: ... Trends, market observers are growing more bullish on the ... reforms to free cash held overseas for tax reason ...
(Date:2/27/2017)... , ... February 27, 2017 , ... The Catalyst ... a few in the Midwest offering premix services and private label organic services. , ... laying hens, according Jos Zamzow, chief operating officer of Dynamite Marketing, which owns the ...
(Date:2/24/2017)... ... ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced ... for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). The ... therapeutic levels of olanzapine for a period of 3 months., “We are honored and ...
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
Breaking Biology Technology: